Advertisement

Thrombotic Thrombocytopenic Purpura and Thrombotic Microangiopathy

  • Kenjiro Honda
  • Kent Doi
Chapter

Abstract

  • Plasma exchange (PE) should be immediately undergone in the probable cases of thrombotic thrombocytopenic purpura (TTP)/thrombotic microangiopathy (TMA) with thrombocytopenia, erythrocyte fragmentation, and hemolytic anemia.

  • Replacement of 1–1.5 times the plasma volume with fresh frozen plasma (FFP) during a single procedure of PE is appropriate. PE should be continued until recovery of appropriate laboratory test values and resolution of neurological symptoms, usually after daily PE for 3–5 days.

  • The effectiveness of PE is controversial, especially in O157-induced hemolytic-uremic syndrome (HUS)/TMA in children

Keywords

Plasma Exchange Disseminate Intravascular Coagulation Fresh Freeze Plasma Thrombotic Thrombocytopenic Purpura Inhibitor Titer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–84PubMedCrossRefGoogle Scholar
  2. 2.
    Scheiflinger F, Knöbl P, Trattner B et al (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102:3241–3PubMedCrossRefGoogle Scholar
  3. 3.
    Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–7PubMedCrossRefGoogle Scholar
  4. 4.
    Novitzky N, Jacobs P, Rosenstrauch W (1994) The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? Br J Haematol 87:317–20PubMedCrossRefGoogle Scholar
  5. 5.
    Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K et al (1998) Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128:541–4PubMedCrossRefGoogle Scholar
  6. 6.
    Bennett CL, Davidson CJ, Raisch DW et al (1999) Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 159:2524–8PubMedCrossRefGoogle Scholar
  7. 7.
    Swisher KK, Terrell DR, Vesely SK et al (2009) Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 49:873–87PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Nephrology and EndocrinologyUniversity Hospital, The University of TokyoTokyoJapan
  2. 2.Department of Emergency and Critical Care MedicineUniversity Hospital, The University of TokyoTokyoJapan

Personalised recommendations